Nice uote From MD Anderson President
MD Anderson President Ron DePinho, M.D., said:
Genetically engineering our patients’ immune-system T cells to efficiently attack and destroy cancer cells represents one of the most exciting approaches with curative potential in oncology today. We believe coupling MD Anderson’s unique CAR T cell approach with the powerful technologies of ZIOPHARM and Intrexon will allow us to build T cells that hit cancer harder, with greater precision, under tighter control and with potentially fewer side effects for patients. This agreement ranks as one of MD Anderson’s most substantial collaborations and will provide significant resources to fuel its mission of Making Cancer History
ridiculous sell off
Summit Research Says CyberArk's Cutting Edge Technology Is Appealing To Many Businesses, Says Cisco And IBM Would Also Have Use For CyberArk Assets, Expects Consolidation In Sector And Believes CyberArk Could Go For A PremiumEddie Staley , Benzinga Staff Writer
Do the DD Amazing Drug
he's on to the next multibagger.
CNA Finance 6/24/15 Synergy Pharmaceuticals (SGYP) Stock Climbs Back Up
Moving forward, I’m expecting to see positive news from Synergy Pharmaceuticals in both the short and long term view. Short Term – In the short run, get ready for more big gains, Synergy Pharmaceuticals got plenty of potential for upside growth. Long Term – In the long run, I’m also expecting to see incredibly bullish activity. First off, I’m very impressed with the results of plecanatide thus far; and think that the drug will become even more impressiveafter the release of data from the study that was initiated yesterday.Also, Synergy Pharmaceuticals has demonstrated the fact that they have strong management and a strong core team time and time again
finally a co. where insiders aren't selling
Sentiment: Strong Buy
J&J buys into Achillion's hep C pipeline for up to $1.1B
May 20, 2015 | By Damian Garde
Johnson & Johnson ($JNJ), fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' ($ACHN) pipeline of antiviral treatments.
Under the deal, J&J is making a $225 million investment in its partner and promising up to $905 million in milestone payments in order to get its hands on a group of in-development hep C treatments. The plan is to develop Achillion's drugs in combination with one another and, ideally, come up with a regimen thcan cure the infection in as few as four weeks. Leading the pipeline is ACH-3102, Achillion's Phase II NS5A inhibitor, followed by the complementary ACH-3422 and sovaprevir.
aj5rose That is a lie Went To SEC Forms- Insiders Have Only Sold 15,000 In The Last 2 Years